(Q43441821)

English

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

scientific article published on 4 November 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

brain metastasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

author name string

C Zhou

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Y Cheng

3

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

S Lu

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

G-Y Chen

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

C Huang

6

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Y-S Huang

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

H-H Yan

8

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

S Ren

9

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Y Liu

10

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

J-J Yang

11

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

publication date

4 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

993-999

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Identification of prognostic factors in patients with brain metastases: a review of 1292 patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Multimodality management of non-small cell lung cancer patients with brain metastases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Treatment of brain metastases: chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Update in the treatment of brain metastases from lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Whole-brain radiotherapy in the management of brain metastasis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS529

21 January 2018

Identifiers

10.1093/ANNONC/MDS529

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43441821&oldid=1613598829"